Information Journal Paper
APA:
Copy. (2017). Preclinical antitumor efficacy of BAY 1129980-a novel auristatin-based anti-C4. 4A (LYPD3) antibody-drug conjugate for the treatment of non-small cell lung cancer. MOLECULAR CANCER THERAPEUTICS, 16(5), 893-904. SID. https://sid.ir/paper/752425/en
Vancouver:
Copy. Preclinical antitumor efficacy of BAY 1129980-a novel auristatin-based anti-C4. 4A (LYPD3) antibody-drug conjugate for the treatment of non-small cell lung cancer. MOLECULAR CANCER THERAPEUTICS[Internet]. 2017;16(5):893-904. Available from: https://sid.ir/paper/752425/en
IEEE:
Copy, “Preclinical antitumor efficacy of BAY 1129980-a novel auristatin-based anti-C4. 4A (LYPD3) antibody-drug conjugate for the treatment of non-small cell lung cancer,” MOLECULAR CANCER THERAPEUTICS, vol. 16, no. 5, pp. 893–904, 2017, [Online]. Available: https://sid.ir/paper/752425/en